Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

November 30, 2013

Conditions
Pulmonary Embolism
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15 mg twice daily for 21 days, followed by 15 mg once daily

DRUG

Unfractionated heparin

To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)

DRUG

Warfarin

To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)

Trial Locations (31)

457-8510

Nagoya

470-1192

Toyoake

030-8553

Aomori

260-8677

Chiba

285-8741

Sakura

830-8543

Kurume

371-8511

Maebashi

006-8555

Sapporo

920-0293

Kahoku-gun

920-8650

Kanazawa

245-8575

Yokohama

862-8505

Kumamoto

514-8507

Tsu

390-8510

Matsumoto

392-8510

Suwa

951-8520

Niigata

530-8480

Osaka

537-8511

Osaka

553-0003

Osaka

589-8511

Sayama

565-8565

Suita

840-8571

Saga

424-8636

Shizuoka

329-0498

Shimotsuke

113-8519

Bunkyo-ku

113-8655

Bunkyo-ku

104-8560

Chuoku

173-8610

Itabashi-ku

152-8902

Meguro-ku

141-8625

Shinagawa

162-8655

Shinjuku-ku

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY